PYLOPASS™ | THE BIOACTIVEINGREDIENT AGAINST HELICOBACTER PYLORI

WHAT IS HELICOBACTER PYLORI?

A gram negative, spiral-shaped human pathogen, infecting anestimated 50% of the global population.
One of the most frequent and persistent bacterial infections worldwide.
Associated with several gastrointestinal diseases such as peptic ulcer disease, gastric ulcers, mucosa-associated lymphoid tissue lymphoma and gastric cancer.
Able to adapt and survive in the acidic environment of the stomach, and adhere to the mucosa.
Able to adapt and survive in the acidic environment of the stomach, and adhere to the mucosa.
High levels can lead to increased acute mucosal damage and long-term changes in the gastric mucosa.
Has been classified as a class I carcinogen by the World Health Organization.
High levels can lead to increased acute mucosal damage and long-term changes in the gastric mucosa.
Has been classified as a class I carcinogen by the World Health Organization.

PYLOPASS™ REDUCES BACTERIAL LOAD OF HELICOBACTER PYLORI

A patented strain of Lactobacillus reuteri that was identified in a detailed, multi-year screening process from several thousand food grade strains.
Has been selected to specifically recognize and bind Helicobacter pylori under harsh stomach conditions.
Exhibits co-aggregation mechanism as a unique and selective mode of action.
Has a shelf-life of minimum 3 years at room temperature, with guaranteed high activity.

PYLOPASS™ SUPPLEMENTATION SIGNIFICANTLY REDUCES H. PYLORI LOAD

Reduction of H. pylori levels in the stomach is demonstrated across all published clinical studies.
Study 1 and 2 demonstrated significant reduction at two and six months after consumption of Pylopass™.
Study 3 demonstrated eradication of H. pylori in several cases.
No side-effects seen.

NOTES: ¹³C-Urea Breath Test is a way of testing for Helicobacter pylori bacterium.

PYLOPASS™ SUPPLEMENTATION IMPROVES QUALITY OF LIFE

Increase in well-being after eating from 50% to 75% of the subjects in Study 3 following 14 and 28 days of supplementation with Pylopass™.

REFERENCES:

Mehling H & Busjahn A (2013) Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to H. pylori control. Nutrients 5: 3062-3072.
Holz C. et al (2014) Significant reduction of Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A pilot study. Probiotics & Antimicro. Prot. 7: 91-100.
Bordin DS et al. (2016) Efficacy and safety of Lactobacillus reuteri DSMZ17648 in Helicobacter pylori infection with no indications for absolute eradication therapy. THERAPIST. 5, www.lvrach.ru.

Recent Posts